Alnylam Pharmaceuticals, Inc. (ALNY) EPS Estimated At $-1.48

April 21, 2018 - By Darrin Black

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) LogoInvestors sentiment increased to 2.03 in Q4 2017. Its up 1.11, from 0.92 in 2017Q3. It is positive, as 27 investors sold Alnylam Pharmaceuticals, Inc. shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported.
27 were reported by Earnest Partners Ltd. Boothbay Fund Mgmt Lc accumulated 3,332 shares or 0.06% of the stock. Vanguard Gru invested in 7.26 million shares. Employees Retirement Systems Of Ohio, a Ohio-based fund reported 37,191 shares. Aqr Cap Mngmt Limited Com invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Citadel Advisors Ltd Liability Company stated it has 57,507 shares or 0% of all its holdings. Legal & General Group Inc Inc Public Limited Com has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 106,472 shares. 27,035 were reported by Amp Capital Investors Limited. Nomura Holdg reported 5,488 shares. Moreover, New York State Common Retirement Fund has 0.03% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 217,081 shares. Cubist Systematic Strategies Ltd has invested 0.13% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Emerald Advisers Pa reported 14,863 shares or 0.07% of all its holdings. Royal Bancorp Of Canada reported 2,687 shares stake. Hall Laurie J Trustee has 3,800 shares for 0.28% of their portfolio. Winfield reported 5 shares or 0% of all its holdings.

Since January 4, 2018, it had 0 insider purchases, and 10 selling transactions for $38.04 million activity. Shares for $4.84 million were sold by Mason Michael on Thursday, January 4. 17,117 shares valued at $2.57M were sold by Ausiello Dennis A on Tuesday, March 13. Greenstreet Yvonne sold 7,221 shares worth $985,958. SCHIMMEL PAUL sold $4.17 million worth of stock. On Tuesday, March 13 the insider SHARP PHILIP A sold $2.24 million. On Wednesday, March 14 Greene Barry E sold $5.50M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 38,460 shares.

Analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report $-1.48 EPS on May, 4.They anticipate $0.23 EPS change or 18.40 % from last quarter’s $-1.25 EPS. After having $-1.48 EPS previously, Alnylam Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.34% or $1.29 during the last trading session, reaching $97.48. About 875,228 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since April 21, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 15 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 11 have Buy rating, 1 Sell and 3 Hold. Therefore 73% are positive. Alnylam Pharmaceuticals had 30 analyst reports since October 30, 2017 according to SRatingsIntel. On Monday, March 12 the stock rating was maintained by FBR Capital with “Buy”. The firm has “Overweight” rating given on Wednesday, November 8 by Barclays Capital. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Friday, January 19 by FBR Capital. The rating was maintained by FBR Capital with “Buy” on Friday, February 2. Jefferies maintained the shares of ALNY in report on Friday, February 9 with “Buy” rating. As per Friday, December 15, the company rating was maintained by Piper Jaffray. JMP Securities maintained the shares of ALNY in report on Tuesday, April 3 with “Buy” rating. The stock has “Sell” rating by Nomura on Friday, February 9. Jefferies maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Monday, January 8. Jefferies has “Buy” rating and $145.0 target. The stock has “Buy” rating by BMO Capital Markets on Thursday, February 8.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $9.77 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The company??s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.